Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
Immune checkpoint
DOI:
10.3389/fimmu.2022.961350
Publication Date:
2022-09-12T06:44:03Z
AUTHORS (9)
ABSTRACT
Background The main objective of this study was to analyze the effects KRAS/TP53 mutation status and tumor sideness on immune microenvironment colorectal cancer using integrated scRNA-seq data. Methods A total 78 datasets, comprising 42 treatment-naive tumors, 13 adjacent tissues 23 normal mucosa were included. Standardized Seurat procedures applied identify cellular components with canonical cell marks. batch-effect assessed corrected harmony algorithm. scMetabolism algorithm used for single-cell metabolic analysis. results clinical significance further validated immunofluorescent-staining TCGA-COAD datasets. Immune-infiltration scores bulk-RNA-seq data estimated ssGSEA. presto-wilcoxauc differentially enriched genes or pathways across different subgroups. Two-sided p-value less than 0.05 considered statistically significant. Results We refined landscape functional subtypes, especially T cells myeloid cells, mucosa, tissue. existence function two states exhausted CD8 + (Tex) subtypes in cancer, FOLR2 LYVE1 macrophages indicating unfavorable prognosis identified validated. diverse reshaped checkpoint ligands/receptors (ICLs/ICRs) expression pattern. Importantly, dual mutations significantly reduced major energy functions promoted cell-to-cell communications towards immunosuppression cancers. revealed LAG3, CD24-SIGLEC10 HBEGF-CD9 as potential therapeutic targets mutant Conclusions that underwent a gradual remodeling an enrichment immunosuppressive from regions Moreover, we heterogeneity tumor-infiltrating suggested may impair antitumor immunity by reducing metabolism reshaping interactions toward immunosuppression.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (76)
CITATIONS (18)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....